Advertisement

Topics

Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth [Report Updated: 01012019] Prices from USD $4995

01:03 EST 21 Jan 2019 | BioPortfolio Report Blog

Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth


Summary


The women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.


The women's health market is relatively small considering the high prevalence of many women's health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.


This report covers all indications within women's health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome PCOS, cervical intraepithelial neoplasia CIN, menopausal disorders and infertility.


Scope


There are 277 pipeline products in active development for women's health disorders. Which molecule types and molecular targets are most prominent within the pipeline?

MerckCo and Bayer currently represent leading companies within women's health. Will they maintain this dominance over the forecast period?

Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women's health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?

The influx of a number of recent market entrants and latestage pipeline products will have a considerable impact on the women's health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?

In total, 246 licensing deals relating to women's health products have been completed since 2006. Which types of assets attracted the largest deal values?


Reasons to buy


Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.

Analyze the women's health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.

Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.

Predict growth in market size by examining multiscenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.

Identify commercial opportunities in the women's health deals landscape by analyzing trends in licensing and codevelopment deals.

Original Article: Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth [Report Updated: 01012019] Prices from USD $4995

NEXT ARTICLE

More From BioPortfolio on "Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth [Report Updated: 01012019] Prices from USD $4995"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Obstetrics and gynaecology
Fertility Menopause Obstetrics & Gynaecology Osteoporosis Women's Health Obstetrics and gynaecology comprises the care of the pregnant woman, her unborn child and the management of diseases specific to women. Most consultant...

Menopause
The menopause is a natural event for all women; the ovaries no longer produce estrogen and progesterone. This can be due to natural aging (usual age of onset is 51 years), or through chemotherapy and surgery on the ovaries. The changing balance of the ho...